Experimental Nasal Sprays for COVID-19: Mechanisms, Pipeline, and Why They're Not Ready Yet

Intranasal sprays aim to intercept SARS-CoV-2 at its primary entry point—the nasal mucosa. While none are currently FDA-approved for COVID-19 treatment or prevention, multiple candidates are advancing through clinical development.

Why Nasal Delivery Makes Sense

  • Site-specific action: Achieves high drug concentrations exactly where the virus first replicates.
  • Non-invasive and self-administered: Needle-free, suitable for home or community use.
  • Rapid local onset: Bypasses gastrointestinal absorption and first-pass metabolism.
  • Mucosal immunity induction: Potential to stimulate secretory IgA antibodies—a first-line defense that injected vaccines do not reliably produce.

Investigational Categories

  • Viral entry blockers: Heparin, carrageenan, griffithsin, engineered ACE2 decoys, and nanobodies that bind the spike protein or host receptors.
  • Antiviral formulations: Nasal versions of remdesivir, favipiravir, ensitrelvir, and molnupiravir.
  • Immune modulators: Interferon-α/λ, TLR agonists (e.g., BO-112), and STING agonists to boost innate antiviral responses.
  • Mucosal vaccines: Adenovirus-vectored (AdCOVID), protein subunit (COVI-VAC), and mRNA-LNP nasal vaccines aiming for sterilizing immunity.
  • Broad-spectrum agents: Targeting conserved viral structures for variant resilience.

Clinical Trial Landscape (2024)

  • Phase 2/3 trials are ongoing for several candidates, including ensitrelvir nasal spray, interferon lambda, and multiple mucosal vaccine platforms.
  • Primary endpoints: viral load reduction, symptom duration, transmission blocking, and safety/tolerability.
  • Regulatory path: FDA and EMA require robust efficacy and safety data; correlates of mucosal protection are still being defined.

Key Challenges

  • Mucosal clearance: Mucociliary clearance and swallowing reduce drug dwell time.
  • Dosing consistency: Variability in spray technique, actuation volume, and nasal anatomy.
  • Local side effects: Irritation, taste disturbance, smell alteration.
  • Durability: Duration of protection remains unknown.
  • Manufacturing stability: Formulation stability for mass deployment and storage.

Current Recommendation

Do not use experimental or unauthorized nasal sprays for COVID-19 prevention or treatment. Rely on authorized vaccines, oral antivirals (Paxlovid, Lagevrio), and public health measures. Follow NIH, WHO, and CDC guidelines.

Ear Candling - Related Articles